News Sentiment

NEUP sentiment intelligence

Neuphoria Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed

Weighted score 51 Balanced news tone 44 relevant articles

Exchange NASDAQ United States

Sector Healthcare Market context

Industry Biotechnology Read-through group

Latest close 3.54 Week of 10 Jul 2026

Weighted tone 51/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

73/100 classification confidence.

Company focus 36

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

+4.7% over one week, -19.0% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Number of shareholders of Neuphoria Therapeutics Inc. – NASDAQ:NEUP

Market Reaction

Price moving ahead of tone

57/100 confidence

Primary event Market update 73/100 classification

One-week reaction 4.7% Price confirming higher

Trend fit Trend inactive -19.0% over four weeks

Fair value -40.5% Below fair value

Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance

Positive 9

Neutral 28

Negative 7

Relevance

Why the article matched

Direct first

Direct company coverage 36

Industry context 8

Sector context 0

Sources

Coverage mix

Publishers

Market source 8

TradingView 8

TradingKey 6

simplywall.st 3

Finviz 2

Investing.com 2

DonanımHaber 2

Moomoo 2

Event Lens

What the news is about

Classified themes

Earnings 16

Market update 15

Deals and strategy 8

Analyst action 3

Capital return 1

Balance sheet 1

Sentiment Trail

Score over time

50 baseline

Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 44

Market source Industry context

Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks

Tone: Neutral 50/100
Event: Earnings
Published: 13 Jul 2026 12:30
Source: Market source

TradingView Direct company coverage

Number of shareholders of Neuphoria Therapeutics Inc. – NASDAQ:NEUP

This article provides details on the number of shareholders for Neuphoria Therapeutics Inc. (NASDAQ: NEUP). It indicates that the information is presented by period, value, change, and change percentage, with data sourced from FactSet Research Systems Inc.

Tone: Neutral 50/100
Event: Market update
Published: 11 Jul 2026 02:39
Source: TradingView

Finviz Direct company coverage

NEUP - Neuphoria Therapeutics Inc Latest SEC Filings

This article provides the latest SEC filings and comprehensive financial data for Neuphoria Therapeutics Inc. It includes detailed information on the company's market performance, key financial ratios, insider and institutional ownership, and stock performance metrics. The data c

Tone: Neutral 50/100
Event: Market update
Published: 04 Jul 2026 16:41
Source: Finviz

Stocktwits Direct company coverage

MRK, NEUP Stocks Drop As Merck Scraps Another Alzheimer’s Drug Trial Under Neuphoria Partnership

Merck (MRK) shares dropped over 2% and Neuphoria Therapeutics (NEUP) fell 19% after Merck terminated a mid-stage trial for its Alzheimer's drug, MK-1167, citing business reasons due to insufficient performance. This marks a second discontinuation for a drug developed under their

Tone: Neutral 50/100
Event: Deals and strategy
Published: 01 Jul 2026 18:01
Source: Stocktwits

Fierce Biotech Direct company coverage

Merck halts ph. 2 Alzheimer’s trial after Neuphoria small molecule underwhelms

Merck has discontinued a phase 2 study for its Alzheimer's disease candidate, MK-1167, due to underwhelming efficacy in an interim analysis. This marks another setback for Merck's partner, Neuphoria Therapeutics, which recently faced a failed phase 3 trial for a social anxiety ca

Tone: Neutral 50/100
Event: Market update
Published: 01 Jul 2026 14:35
Source: Fierce Biotech

Investing.com Direct company coverage

Neuphoria confirms merger talks with Scancell Holdings

Neuphoria Therapeutics Inc. confirmed it is in discussions with Scancell Holdings plc regarding a potential acquisition, which would make Scancell a Nasdaq-listed company. The discussions follow speculation in the UK press and come after Neuphoria's lead drug candidate, BNC210, f

Tone: Neutral 50/100
Event: Deals and strategy
Published: 30 Jun 2026 17:42
Source: Investing.com

Market source Direct company coverage

Neuphoria Responds to the announcement made by London-listed Scancell Holdings plc

Neuphoria Therapeutics Inc. has confirmed it is in discussions with London-listed Scancell Holdings plc regarding a potential acquisition. The talks were prompted by speculation in the UK press and an announcement from Scancell. While discussions are ongoing, Neuphoria emphasizes

Tone: Positive 62/100
Event: Deals and strategy
Published: 28 Jun 2026 16:42
Source: Market source

Bitget Direct company coverage

Neuphoria Therapeutics Inc's stock price recorded a significant increase of 6% in after-hours trading, closing at $4.85.

Neuphoria Therapeutics Inc.'s stock price rose by 6% in after-hours trading to $4.85, amidst light trading volume. The company confirmed it is in acquisition talks with biopharmaceutical company Scancell, which directly influenced the stock's performance.

Tone: Positive 70/100
Event: Deals and strategy
Published: 27 Jun 2026 16:39
Source: Bitget

MT Newswires Direct company coverage

Neuphoria Confirms Business Combination Talks With Scancell

Tone: Neutral 50/100
Event: Market update
Published: 26 Jun 2026 20:36
Source: MT Newswires

TradingView Direct company coverage

Neuphoria Therapeutics Confirms Discussions On Potential Acquisition By Scancell

Neuphoria Therapeutics has confirmed it is in discussions regarding a potential acquisition by Scancell. The brief report, sourced from Reuters via Refinitiv, indicates that further details were not immediately available beyond the confirmation of these talks.

Tone: Positive 67/100
Event: Deals and strategy
Published: 26 Jun 2026 21:09
Source: TradingView

TradingView Direct company coverage

Neuphoria Therapeutics Inc. Actuals & Estimates (NASDAQ:NEUP)

This article provides an overview of Neuphoria Therapeutics Inc. (NASDAQ: NEUP) stock, including its current price, market capitalization, and historical performance. It details financial estimates, such as earnings per share and revenue, and notes that the company does not pay d

Tone: Neutral 50/100
Event: Earnings
Published: 26 Jun 2026 20:09
Source: TradingView

Market source Direct company coverage

Scancell confirms advanced talks over reverse merger with Neuphoria

Scancell Holdings PLC, a developer of cancer immunotherapies, has confirmed it is in advanced discussions for a reverse merger with US-listed Neuphoria Therapeutics. The all-share transaction could provide Scancell with a Nasdaq listing, enhancing its profile among US investors.

Tone: Positive 66/100
Event: Deals and strategy
Published: 26 Jun 2026 14:09
Source: Market source

TradingView Direct company coverage

NEUP Forecast — Price Target — Prediction for 2027

This article provides an overview of Neuphoria Therapeutics Inc. (NEUP) stock, including its current price, market capitalization, and historical performance. It details recent earnings and revenue figures, upcoming earnings dates, and general advice on investing in NEUP stock. T

Tone: Neutral 50/100
Event: Earnings
Published: 26 Jun 2026 14:09
Source: TradingView

Investing.com Direct company coverage

Scancell in talks for reverse merger with Neuphoria Therapeutics

Scancell Holdings plc is in advanced discussions for a potential reverse merger with Neuphoria Therapeutics Inc., an all-share transaction aimed at facilitating a Nasdaq listing for Scancell. This move would enhance Scancell's profile with U.S. investors and includes plans for eq

Tone: Positive 63/100
Event: Deals and strategy
Published: 26 Jun 2026 14:09
Source: Investing.com